These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1324 related items for PubMed ID: 2164434

  • 1. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N, Badsberg JH, Lönnqvist B, Ringdén O, Volin L, Rajantie J, Nikoskelainen J, Keiding N.
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 3. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
    Gale RP, Horowitz MM.
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
    [Abstract] [Full Text] [Related]

  • 4. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Granena A, Gahrton G, De Witte T, Gratwohl A, Reiffers J, Gorin NC.
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [Abstract] [Full Text] [Related]

  • 5. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y, Japan Marrow Donor Program.
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T, Schattenberg A, Preijers F, Raymakers R, Muus P, Wessels J.
    Bone Marrow Transplant; 1993 Apr; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [Abstract] [Full Text] [Related]

  • 8. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 9. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.
    Nachbaur D, Clausen J, Kircher B.
    Eur J Haematol; 2006 May; 76(5):414-9. PubMed ID: 16480430
    [Abstract] [Full Text] [Related]

  • 10. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes.
    Habib K, Lamia T, Amel L, Abdelrahmen A, Saloua L, Hana E, Amine S, Bechir Z, Tarek BO, Assia BH.
    Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248
    [Abstract] [Full Text] [Related]

  • 11. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS.
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [Abstract] [Full Text] [Related]

  • 12. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.
    Garderet L, Labopin M, Gorin NC, Polge E, Fouillard L, Ehninger GE, Ringden O, Finke J, Tura S, Frassoni F.
    Bone Marrow Transplant; 2003 Jan; 31(1):23-9. PubMed ID: 12621503
    [Abstract] [Full Text] [Related]

  • 15. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 16. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C.
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [Abstract] [Full Text] [Related]

  • 19. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Sep; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 20. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH, Saunders EF, Calderwood S, Doyle JJ.
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.